Archives of Virology

, Volume 162, Issue 1, pp 247–257 | Cite as

Comparison of immune responses to attenuated rabies virus and street virus in mouse brain

  • Fa-ming Miao
  • Shou-feng Zhang
  • Shu-chao Wang
  • Ye Liu
  • Fei Zhang
  • Rong-liang HuEmail author
Original Article


Rabies is a lethal neurological disease caused by the neurotropic rabies virus (RABV). To investigate the innate immune response in the brain during rabies infection, key gene transcripts indicative of innate immunity in a mouse model system were measured using real-time RT-PCR. Mice were infected via the intracerebral or intramuscular route with either attenuated rabies virus (SRV9) or pathogenic rabies virus (BD06). Infection with SRV9 resulted in the early detection of viral replication and the rapid induction of innate immune response gene expression in the brain. BD06 infection elicited innate immune response gene expression during only the late stage of infection. We measured Na-fluorescein uptake to assess blood-brain barrier (BBB) permeability, which was enhanced during the early stage of SRV9 infection and significantly enhanced during the late stage of BD06 infection. Furthermore, early SRV9 replication increased the maturation and differentiation of dendritic cells (DCs) and B cells in the inguinal lymph nodes and initiated the generation of virus-neutralizing antibodies (VNAs), which cooperate with the innate immune response to eliminate virus from the CNS. However, BD06 infection did not stimulate VNA production; thus, the virus was able to evade the host immune response and cause encephalitis. The rabies virus phosphoprotein has been reported to counteract IFN activation. In an in vitro study of the relationship between IFN antagonism and RABV pathogenicity, we demonstrated that SRV9 more strongly antagonized IFN activity than did BD06. Therefore, there is no positive relationship between the IFN antagonist activity of the virus and its pathogenicity.


Reverse Transcription Polymerase Chain Reaction Rabies Rabies Virus BD06 Infection Rabies Virus Strain 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This project was funded by the National Natural Science Foundation of China (31472176) and the Key Project of National Natural Science Foundation of China (30630049).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.


  1. 1.
    Shwiff S, Hampson K, Anderson A (2013) Potential economic benefits of eliminating canine rabies. Antiviral Res 98(2):352–356CrossRefPubMedGoogle Scholar
  2. 2.
    Feder HM Jr, Petersen BW, Robertson KL, Rupprecht CE (2012) Rabies: still a uniformly fatal disease? Historical occurrence, epidemiological trends, and paradigm shifts. Curr Infect Dis Rep 14:408–422CrossRefPubMedGoogle Scholar
  3. 3.
    Hooper DC, Morimoto K, Bette M, Weihe E, Koprowski H, Dietzschold B (1998) Collaboration of antibody and inflammation in clearance of rabies virus from the central nervous system. J Virol 72:3711–3719PubMedPubMedCentralGoogle Scholar
  4. 4.
    Appolinario CM, Jackson AC (2015) Antiviral therapy for human rabies. Antivir Ther 20:1–10CrossRefPubMedGoogle Scholar
  5. 5.
    Rubin J, David D, Willoughby RE Jr, Rupprecht CE, Garcia C, Guarda DC, Zohar Z, Stamler A (2009) Applying the Milwaukee protocol to treat canine rabies in Equatorial Guinea. Scand J Infect Dis 41:372–375CrossRefPubMedGoogle Scholar
  6. 6.
    Takeuchi O, Akira S (2009) Innate immunity to virus infection. Immunol Rev 227:75–86CrossRefPubMedGoogle Scholar
  7. 7.
    Wang ZW, Sarmento L, Wang Y, Li XQ, Dhingra V, Tseggai T, Jiang B, Fu ZF (2005) Attenuated rabies virus activates, while pathogenic rabies virus evades, the host innate immune responses in the central nervous system. J Virol 79:12554–12565CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Gnanadurai CW, Yang Y, Huang Y, Li Z, Leyson CM, Cooper TL, Platt SR, Harvey SB, Hooper DC, Faber M, Fu ZF (2015) Differential host immune responses after infection with wild-type or lab-attenuated rabies viruses in dogs. PLoS Negl Trop Dis 9:e0004023CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Pestka S, Krause CD, Walter MR (2004) Interferons, interferon-like cytokines, and their receptors. Immunol Rev 202:8–32CrossRefPubMedGoogle Scholar
  10. 10.
    Brzozka K, Finke S, Conzelmann KK (2005) Identification of the rabies virus alpha/beta interferon antagonist: phosphoprotein P interferes with phosphorylation of interferon regulatory factor 3. J Virol 79:7673–7681CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Brzozka K, Finke S, Conzelmann KK (2006) Inhibition of interferon signaling by rabies virus phosphoprotein P: activation-dependent binding of STAT1 and STAT2. J Virol 80:2675–2683CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Ministry of Science and Technology of the People’s Republic of China. Accessed 30 Sept 2006
  13. 13.
    Zhao J, Wang S, Zhang S, Liu Y, Zhang J, Zhang F, Mi L, Hu R (2014) Molecular characterization of a rabies virus isolate from a rabid dog in Hanzhong District, Shaanxi Province, China. Arch Virol 159:1481–1486CrossRefPubMedGoogle Scholar
  14. 14.
    Zhao J, Liu Y, Zhang S, Fang L, Zhang F, Hu R (2014) Experimental oral immunization of ferret badgers (Melogale moschata) with a recombinant canine adenovirus vaccine CAV-2-E3Delta-RGP and an attenuated rabies virus SRV9. J Wildl Dis 50:374–377CrossRefPubMedGoogle Scholar
  15. 15.
    Meslin FX, Kaplan MM, Koprowski H (1996) Laboratory techniques in rabies, 4th edn. World Health Organization, Geneva, pp 80–168Google Scholar
  16. 16.
    Wong ML, Medrano JF (2005) Real-time PCR for mRNA quantitation. Biotechniques 39:75–85CrossRefPubMedGoogle Scholar
  17. 17.
    Deng HK, Unutmaz D, KewalRamani VN, Littman DR (1997) Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature 388:296–300CrossRefPubMedGoogle Scholar
  18. 18.
    Phares TW, Kean RB, Mikheeva T, Hooper DC (2006) Regional differences in blood–brain barrier permeability changes and inflammation in the apathogenic clearance of virus from the central nervous system. J Immunol 176:7666–7675CrossRefPubMedGoogle Scholar
  19. 19.
    Ito N, Moseley GW, Blondel D, Shimizu K, Rowe CL, Ito Y, Masatani T, Nakagawa K, Jans DA, Sugiyama M (2010) Role of interferon antagonist activity of rabies virus phosphoprotein in viral pathogenicity. J Virol 84:6699–6710CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Dietzschold B, Schnell M, Koprowski H (2005) Pathogenesis of rabies. Curr Top Microbiol Immunol 292:45–56PubMedGoogle Scholar
  21. 21.
    Hemachudha T, Ugolini G, Wacharapluesadee S, Sungkarat W, Shuangshoti S, Laothamatas J (2013) Human rabies: neuropathogenesis, diagnosis, and management. Lancet Neurol 12:498–513CrossRefPubMedGoogle Scholar
  22. 22.
    World Health Organization (2013) WHO expert consultation on rabies. Second report. Technical report series, back cover, pp 1–139Google Scholar
  23. 23.
    Gnanadurai CW, Zhou M, He W, Leyson CM, Huang CT, Salyards G, Harvey SB, Chen Z, He B, Yang Y, Hooper DC, Dietzchold B, Fu ZF (2013) Presence of virus neutralizing antibodies in cerebral spinal fluid correlates with non-lethal rabies in dogs. PLoS Negl Trop Dis 7:e2375CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Schutsky K, Curtis D, Bongiorno EK, Barkhouse DA, Kean RB, Dietzschold B, Hooper DC, Faber M (2013) Intramuscular inoculation of mice with the live-attenuated recombinant rabies virus TriGAS results in a transient infection of the draining lymph nodes and a robust, long-lasting protective immune response against rabies. J Virol 87:1834–1841CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Tolson ND, Charlton KM, Lawson KF, Campbell JB, Stewart RB (1988) Studies of ERA/BHK-21 rabies vaccine in skunks and mice. Can J Vet Res = Revue canadienne de recherche veterinaire 52:58–62PubMedGoogle Scholar
  26. 26.
    Hooper DC, Phares TW, Fabis MJ, Roy A (2009) The production of antibody by invading B cells is required for the clearance of rabies virus from the central nervous system. PLoS Negl Trop Dis 3:e535CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Hooper DC, Roy A, Barkhouse DA, Li J, Kean RB (2011) Rabies virus clearance from the central nervous system. Adv Virus Res 79:55–71CrossRefPubMedGoogle Scholar
  28. 28.
    Liao PH, Yang HH, Chou PT, Wang MH, Chu PC, Liu HL, Chen LK (2012) Sufficient virus-neutralizing antibody in the central nerve system improves the survival of rabid rats. J Biomed Sci 19:61CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Roy A, Hooper DC (2008) Immune evasion by rabies viruses through the maintenance of blood–brain barrier integrity. J Neurovirol 14:401–411CrossRefPubMedGoogle Scholar
  30. 30.
    Dubois B, Bridon JM, Fayette J, Barthelemy C, Banchereau J, Caux C, Briere F (1999) Dendritic cells directly modulate B cell growth and differentiation. J Leukoc Biol 66:224–230PubMedGoogle Scholar
  31. 31.
    Qian L, Qian C, Chen Y, Bai Y, Bao Y, Lu L, Cao X (2012) Regulatory dendritic cells program B cells to differentiate into CD19hiFcgammaIIbhi regulatory B cells through IFN-beta and CD40L. Blood 120:581–591CrossRefPubMedGoogle Scholar
  32. 32.
    Barkhouse DA, Garcia SA, Bongiorno EK, Lebrun A, Faber M, Hooper DC (2015) Expression of interferon gamma by a recombinant rabies virus strongly attenuates the pathogenicity of the virus via induction of type I interferon. J Virol 89:312–322CrossRefPubMedGoogle Scholar
  33. 33.
    Wen Y, Wang H, Wu H, Yang F, Tripp RA, Hogan RJ, Fu ZF (2011) Rabies virus expressing dendritic cell-activating molecules enhances the innate and adaptive immune response to vaccination. J Virol 85:1634–1644CrossRefPubMedGoogle Scholar
  34. 34.
    Zhou M, Wang L, Zhou S, Wang Z, Ruan J, Tang L, Jia Z, Cui M, Zhao L, Fu ZF (2015) Recombinant rabies virus expressing dog GM-CSF is an efficacious oral rabies vaccine for dogs. Oncotarget 6:38504–38516PubMedPubMedCentralGoogle Scholar
  35. 35.
    Wang Y, Tian Q, Xu X, Yang X, Luo J, Mo W, Peng J, Niu X, Luo Y, Guo X (2014) Recombinant rabies virus expressing IFNalpha1 enhanced immune responses resulting in its attenuation and stronger immunogenicity. Virology 468–470:621–630CrossRefPubMedGoogle Scholar
  36. 36.
    Roy A, Phares TW, Koprowski H, Hooper DC (2007) Failure to open the blood–brain barrier and deliver immune effectors to central nervous system tissues leads to the lethal outcome of silver-haired bat rabies virus infection. J Virol 81:1110–1118CrossRefPubMedGoogle Scholar
  37. 37.
    Lafon M (2011) Evasive strategies in rabies virus infection. Adv Virus Res 79:33–53CrossRefPubMedGoogle Scholar
  38. 38.
    Rieder M, Brzozka K, Pfaller CK, Cox JH, Stitz L, Conzelmann KK (2011) Genetic dissection of interferon-antagonistic functions of rabies virus phosphoprotein: inhibition of interferon regulatory factor 3 activation is important for pathogenicity. J Virol 85:842–852CrossRefPubMedGoogle Scholar
  39. 39.
    Masatani T, Ozawa M, Yamada K, Ito N, Horie M, Matsuu A, Okuya K, Tsukiyama-Kohara K, Sugiyama M, Nishizono A (2015) Contribution of the interaction between rabies virus P protein and IKKepsilon to the inhibition of type I interferon induction signaling. J Gen Virol 97:316–326CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2016

Authors and Affiliations

  • Fa-ming Miao
    • 1
  • Shou-feng Zhang
    • 1
  • Shu-chao Wang
    • 1
  • Ye Liu
    • 1
  • Fei Zhang
    • 1
  • Rong-liang Hu
    • 1
    Email author
  1. 1.Laboratory of Epidemiology, Institute of Military VeterinaryAcademy of Military Medical Sciences, Key Laboratory of Jilin Province for Zoonosis Prevention and ControlChangchunChina

Personalised recommendations